A case report of the coagulation management of an adult with moderate haemophilia A undergoing transcatheter aortic valve implantation

Clicks: 20
ID: 320522
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #127 of 411 articles by views in European Heart Journal - Case Reports

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 411 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Haemophilia A is an X-linked bleeding disorder resulting from factor VIII deficiency. While surgical management requires the correction of factor VIII levels by the administration of factor VIII concentrate, antiplatelet therapy after lower-risk cardiac surgery/procedures (such as transcatheter aortic valve implantation - TAVI) is not yet standardised. This report describes the management of a patient with moderate haemophilia A undergoing TAVI for severe aortic stenosis.. Case summary A 76-year-old man with untreated haemophilia A was admitted with traumatic bleeding. After initial stabilisation, he developed acute heart failure due to newly discovered severe aortic stenosis. TAVI procedure was performed by transfemoral access according to multidisciplinary team-discussion; a bio-prosthetic valve was successfully implanted. We outline the periprocedural haemostatic management, which included factor VIII replacement therapy to achieve guideline-recommended activity levels, followed by progressive dose reduction. In view of the high bleeding risk and absence of significant coronary artery disease, antiplatelet therapy was limited to a short course. The procedure was successful, with no bleeding complications. Conclusion Although evidence is limited to case reports, TAVI appears to be feasible and safe in patients with haemophilia A. Maintaining high factor VIII activity levels and minimizing antithrombotic exposure through multidisciplinary evaluation can effectively reduce haemorrhagic risk. Our case, in line with previous reports, resulted in no bleeding complications.
Reference Key
openalex_W7167944505 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Vincent Roger Gianolli, Erica Terazzi, Chiara Trotti, Eugenia Biguzzi, Angelo Di Simone, Andrea Menafoglio, Andrea Demarchi
Are you one of these authors? Claim your profile
Journal European Heart Journal - Case Reports
Year 2026
DOI
10.1093/ehjcr/ytag484
URL
https://doi.org/10.1093/ehjcr/ytag484
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.